‘The invisible threat': Air pollution exposure over time raises the risk of dementia, study finds
The analysis, published in The Lancet Planetary Health journal, is the largest study to date to confirm the connection between air pollution and brain health, though questions remain about the actual mechanism and the time period when people are most at risk.
About 57 million people worldwide have dementia, which occurs when nerve cells' connections in the brain are lost or damaged. Scientists have identified a handful of risk factors, including air pollution, but until now, they haven't known which pollutants were riskiest.
For the new analysis, researchers from the University of Cambridge in the United Kingdom looked at data from 51 reports spanning nearly 30 million people, mostly in high-income countries.
They found strong links between dementia risks and exposure to fine particulate matter from sources such as car emissions, power plants, and dust, as well as nitrogen dioxide from the burning of fuel and soot from things like car exhaust and burning wood.
Related
People who breathe dirty air are at higher risk of brain tumours that do not usually cause cancer
These pollutants appear to have stronger ties to vascular dementia, which is caused by reduced blood flow to the brain, than to Alzheimer's disease, the most common form of dementia – but those differences may not be significant.
'Air pollution is not just an environmental issue – it's a serious and growing threat to our brain health,' Dr Isolde Radford, senior policy manager at Alzheimer's Research UK, said in a statement.
Scientists still don't know whether air pollution actually causes dementia or what the biological pathways could be. But they think pollution may cause inflammation and oxidative stress – which can damage cells and DNA – in the brain, both of which have been linked to the onset and progression of dementia.
'The body has no effective defence against the ultrafine particle cocktails we generate outdoors, especially from traffic, and indoors, for example, in heating our homes using stoves,' Barbara Maher, a professor of environmental magnetism at Lancaster University in the UK who was not involved with the study, said in a statement.
Related
One in three people worldwide are breathing in household air pollution, researchers warn
The analysis has some limitations. It is notoriously difficult to track exactly which pollutants a specific person is exposed to over time, how these pollutants interact with each other, and how this affects human health.
This study, along with many others, estimated people's air pollution exposure based on their home address. It also isn't clear when in life this exposure matters most, though researchers believe it may be a period of years or even decades.
'A better approach [to research] is sorely needed,' Dr Tom Russ, a dementia specialist who researches old age psychiatry at the University of Edinburgh, said in a statement.
Related
Air purifiers, masks and staying indoors: How to reduce your risk from air pollution
'This article answers the question of whether air pollution exposure is associated with dementia better than previous work, but we still need better research to clarify how and why air pollution might be bad for the brain,' added Russ, who was not involved with the study.
Even so, scientists and dementia groups called for governments to enact stricter air quality rules and take other steps to reduce people's exposure to air pollution.
'Far more needs to be done to tackle this invisible threat,' Radford said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
SurgiBox Achieves CE Mark for SurgiField System Devices to Improve Access to Safe Surgery at the Point of Need
CE Certification positions SurgiBox for global expansion and robust sales acceleration The Complete SurgiField System CE Mark CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- SurgiBox, a medical technology company committed to improving access to safe, clean surgery at the point of need, announced today it has received the CE Mark under MDR for the medical devices that comprise its flagship product, the SurgiField™ System. The CE Mark under the European Union's Medical Device Regulation (MDR 2017/745) standards certifies compliance with stringent health, safety, and environmental protection standards required for medical devices in the European Union. SurgiBox received CE Mark approval today for the SurgiBubble™, the sterile device component of its SurgiField™ System, an ultraportable technology platform integrating intraprocedural environmental control and personal protective equipment. Combined with the previously approved electronic filtration system, the complete SurgiField System is now ready for market deployment. This milestone, spearheaded by SurgiBox co-founder Sashidhar Jonnalagedda and CTO Atif Rakin, marks the successful certification of conformity with the EU's Medical Device Regulation (MDR 2017/745) and ISO 13485:2016 standards - paving the way for commercial distribution across Europe and other key international markets. The SurgiField System is a first-of-its-kind, ultraportable surgical environment that protects both patients and surgical teams from cross-contamination with bodily fluids. Medical professionals apply the disposable SurgiBubble to the patient's surgical site using standard draping techniques. They then activate operating room-quality HEPA airflow through the battery-powered Smart Control Module and pop-up frame. Surgeons insert their arms through integrated sleeve ports - similar to putting on surgical gowns - and proceed with the procedure as normal. The CE Mark approval is supported by comprehensive testing, including preclinical laboratory studies and usability data. These studies consistently demonstrated that the SurgiBubble protects the surgical site from the outside environment. Additionally, the SurgiField System seamlessly integrates into surgical workflows across diverse environments, from field conditions to established medical facilities. Timely access to safe, clean surgery is a massive challenge globally across the spectrum of healthcare resources, with an estimated 5 billion people chronically lacking consistent access to safe surgery, resulting in 18 million preventable deaths annually. Even in high-resource settings with quality surgical facilities, ballooning costs, logistical challenges, and rising wait times have pushed surgeons and health systems to look toward alternative settings like hospital bedside, ambulatory surgery centers, birth centers, and clinic offices. 'This MDR CE certification marks a major inflection point for SurgiBox,' said Dr. Mike Teodorescu, CEO of SurgiBox. 'It reflects years of hard work and dedication to rigorous design, testing, and regulatory compliance, in collaboration with leading clinicians around the world who make up the 'SurgiClub.' With the new MDR CE Mark approval, we're finally ready to answer clinicians' requests to bring the SurgiField System to their patients.' 'Ambit Health Ventures is immensely proud of SurgiBox's team and the invaluable support from its partners," said Dr. Sam Goldberger, a retired oculoplastic surgeon who is now a Board Director at SurgiBox and Managing Partner of Ambit Health Ventures. "This CE Mark is a significant milestone, validating our long-term commitment to making safe surgery accessible to all, especially those facing crises. Furthermore, SurgiBox technology promises to expand access to safe surgery in areas with limited operating room infrastructure. Looking ahead, SurgiBox offers the potential to reduce healthcare costs significantly. The technology enables safe surgery to be performed in any setting, even non-sterile ones, within hospitals and private practices - procedures that would otherwise require a traditional expensive operating room. This CE Mark allows us to scale our global impact significantly.' SurgiBox is now actively fulfilling global sales orders and ramping up operational readiness to support a rapidly growing sales pipeline. The company is bolstering its supply chain and expanding its network of distributors to ensure smooth delivery and outstanding customer satisfaction. Backed by new strategic partnerships, SurgiBox is accelerating market penetration and expanding its global footprint. The company has simultaneously launched a fundraising campaign to ensure the resources and capital needed to meet rising demand - offering investors the opportunity to support and share in its next phase of growth. About SurgiBox: Headquartered in Cambridge, MA, USA, SurgiBox Inc. is a medical technology company committed to bringing safe surgery to patients, anytime, anywhere. For further information, please see: Media Contact: press@ Sales Contact: sales@ Provider Contact: surgiclub@ Photos accompanying this announcement are available at: while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Fast Company
25 minutes ago
- Fast Company
Sources reveal the Trump administration's plans for cutting U.S. drug prices
The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt 'most favored nation' pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being 'ripped off.' The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America — the industry's main lobby group — has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. 'Prices can come down in the United States without being increased in other countries, and we can still get innovation,' she said. TOP PRIORITY Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. 'This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it,' the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. 'There's a big push from the administration to drive up prices outside the U.S.,' the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca, Bayer and Novo Nordisk signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. 'It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction,' Kaltenboeck said, 'and it doesn't make much sense for them politically.'


Associated Press
26 minutes ago
- Associated Press
Big Data in Healthcare Market Trends and Forecast Report 2025-2035, with Leading Players
DUBLIN--(BUSINESS WIRE)--Aug 7, 2025-- The 'Big Data in Healthcare Market Trends and Forecast Report 2025-2035: By Component, Type of Hardware, Type of Software and Service, Deployment Option, Application Area, Healthcare Vertical, End User, Economic Status, Geography and Leading Players' report has been added to offering. The global big data in healthcare market is estimated to grow from USD 78 billion in 2025, to USD 540 billion by 2035, at a CAGR of 19.20% during the forecast period, to 2035. The integration of big data analytics in the healthcare domain holds immense potential for revolutionizing the industry and unlocking lucrative business opportunities for service providers. The ability to aggregate, analyze, and derive actionable insights from vast amounts of data can enhance clinical decision-making, optimize resource allocation, and improve patient outcomes. Moreover, the integration of predictive analytics and machine learning algorithms with big data can enable early detection of diseases, personalized treatment plans, and precision medicine. This paradigm shift offers service providers the chance to develop innovative solutions, such as cloud-based platforms for real-time monitoring systems, and data-driven diagnostics. Collectively, these advancements have the potential to drastically reduce healthcare costs, enhance operational efficiency, and enable the delivery of higher quality care. As the healthcare industry continues to embrace big data analytics, the magnitude of the transformative impact and the vast business opportunities will become increasingly evident, revolutionizing the landscape for both providers and patients. Big Data in Healthcare Market: Key Insights The report delves into the current state of the big data in healthcare market and identifies potential growth opportunities within the industry. Some key findings from the report include: Big Data in Healthcare Market: Research Coverage Sample Players in the Big Data in Healthcare Market, Profiled in the Report, Include: Key Questions Answered in this Report Reasons to Buy this Report Additional Benefits For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: PROFESSIONAL SERVICES DATA MANAGEMENT HEALTH TECHNOLOGY DATA ANALYTICS OTHER HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 08/07/2025 11:52 AM/DISC: 08/07/2025 11:51 AM